Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia

Correction to: Journal of Hematology & Oncology (2020) 13:78 https://doi.org/10.1186/s13045-020-00909-y

The original article [1] contains an error in Fig. 6b for the image of western blot panels.

Fig. 6

LAMP5-AS1 could serve as a prognostic predictor of MLL leukemia. a Reanalysis of the GSE62190, GSE66917 and GSE67039 data sets with 419 patient samples classified into MLL leukemia and MLL-wt subtypes. LAMP5-AS1 expression presented the highest levels in MLL leukemia. (Mann–Whitney test, p < 0.001). b LAMP5-AS1 and MLL fusion protein levels in 7 paired MLL leukemia patients (initial diagnosis versus complete response, CR), and the MLL fusion protein levels were positively correlated with those of LAMP5-AS1 (△CT) at preliminary diagnosis (Pearson r = -0.8817, p < 0.01). Relative expression (ΔCT) was used to quantify LAMP5-AS1 expression relative to a housekeeping gene (GAPDH). c ROC curve analysis showed that LAMP5-AS1 had high AUC values of 0.7572 (95% confidence interval (CI): 0.6625–0.8519) and 0.9280 (95% CI: 0.8904–0.9620, p < 0.001) in the GSE62190, GSE66917 and GSE67039 data sets (n = 35 for MLL leukemia and n = 384 for MLL-wt) and validation set (n = 58 for MLL and n = 163 for MLL-wt), respectively, with considerably significant sensitivity (sen.) and specificity (spe.) at the optimal cutoff point calculated by Youden’s index. d The 5-year leukemia-free survival of patients with a high expression level of LAMP5-AS1 is less than that of patients with a low LAMP5-AS1 level in MLL leukemia (n = 200, p < 0.01). e A working model proposed for the specific activation of DOT1L/H3K79 methyltransferase by LAMP5-AS1 binding to regulate MLL leukemia self-renewal

The correct presentation of Fig. 6b is shown below.